Literature DB >> 1638523

Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia.

A S Greenberg1, R P Nordan, J McIntosh, J C Calvo, R O Scow, D Jablons.   

Abstract

To investigate whether interleukin 6 (IL-6) might be a potential mediator of the depleted fat reserves observed in malignancy-associated cachexia, we measured lipoprotein lipase (LPL) activity in adipose tissue of mice after administration of IL-6 or tumor necrosis factor and in cultured adipocytes after addition of these cytokines. Injection of IL-6 i.p. reduced adipose tissue LPL activity by 53% within 4.5 to 5.5 h. Injection of tumor necrosis factor elevated serum IL-6 levels and reduced adipose tissue LPL activity by 70%. Both human and murine IL-6 reduced heparin-releasable LPL activity in 3T3-L1 adipocytes in a dose-dependent manner; half-maximal inhibition of LPL activity was achieved with 5000 hybridoma growth factor units/ml. Thus, IL-6 reduces adipose LPL activity and may contribute to the loss of body fat stores associated with some cases of cancer cachexia. Since tumor necrosis factor increases circulating IL-6, some of its effects may be mediated or potentiated by IL-6.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638523

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Linkage and association of the CA repeat polymorphism of the IL6 gene, obesity-related phenotypes, and bone mineral density (BMD) in two independent Caucasian populations.

Authors:  Qing-Yang Huang; Hui Shen; Hong-Yi Deng; Theresa Conway; K Michael Davies; Jin-Long Li; Robert R Recker; Hong-Wen Deng
Journal:  J Hum Genet       Date:  2003-07-26       Impact factor: 3.172

Review 2.  Interleukin 6 as a key regulator of muscle mass during cachexia.

Authors:  James A Carson; Kristen A Baltgalvis
Journal:  Exerc Sport Sci Rev       Date:  2010-10       Impact factor: 6.230

3.  IL-29 promoted obesity-induced inflammation and insulin resistance.

Authors:  Tian-Yu Lin; Chiao-Juno Chiu; Chen-Hsiang Kuan; Fang-Hsu Chen; Yin-Chen Shen; Chih-Hsing Wu; Yu-Hsiang Hsu
Journal:  Cell Mol Immunol       Date:  2019-07-30       Impact factor: 11.530

4.  Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice.

Authors:  Haruo Iguchi; Yuko Aramaki; Shigeaki Maruta; Soichi Takiguchi
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

Authors:  Joan Oliva; Samuel W French; Jun Li; Fawzia Bardag-Gorce
Journal:  Exp Mol Pathol       Date:  2012-03-16       Impact factor: 3.362

6.  Risk factors and mechanisms of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera
Journal:  Pathophysiology       Date:  2008-07-29

Review 7.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 8.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

9.  Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.

Authors:  L Tessitore; P Costelli; F M Baccino
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

Review 10.  HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis.

Authors:  Rabia Nawaz; Sadia Zahid; Muhammad Idrees; Shazia Rafique; Muhammad Shahid; Ammara Ahad; Iram Amin; Iqra Almas; Samia Afzal
Journal:  Inflamm Res       Date:  2017-03-11       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.